MONARCH PHARMACEUTICALS, LLC – Trademark Portfolio

Entity Type: 03

MONARCH PHARMACEUTICALS, LLC holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include MENEST and CORTISPORIN. The owner is based in NEW YORK, NY.

66 Hudson Boulevard East

NEW YORK, NY 100012192

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MENEST
MENEST
Registered 1992
PEDIOTIC
PEDIOTIC
Cancelled 1988
NUCOFED
NUCOFED
Cancelled 1977
VIROPTIC
VIROPTIC
Cancelled 1974
SEPTRA
SEPTRA
Cancelled 1969

Trademark Classifications

MONARCH PHARMACEUTICALS, LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does MONARCH PHARMACEUTICALS, LLC have?

MONARCH PHARMACEUTICALS, LLC has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 cancelled.

What trademark classes does MONARCH PHARMACEUTICALS, LLC file in?

MONARCH PHARMACEUTICALS, LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are MONARCH PHARMACEUTICALS, LLC's most well-known trademarks?

MONARCH PHARMACEUTICALS, LLC's registered trademark portfolio includes well-known marks such as MENEST and CORTISPORIN. These are among 2 currently registered trademarks in the portfolio.

What is MONARCH PHARMACEUTICALS, LLC's trademark registration success rate?

MONARCH PHARMACEUTICALS, LLC has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.